Abstracts tagged "mixed connective tissue disease (MCTD) and systemic lupus erythematosus (SLE)"

Abstract Number: 2124 • 2017 ACR/ARHP Annual Meeting
Mixed Connective Tissue Disorder Has Higher Prevalence of Arthritis and Use of Methotrexate Than Systemic Lupus Erythematosus
Gunasekaran Sambandam^1,2, Dr. Varun Dhir³, Dr. Mahesh Prakash⁴, Ranjana Minz⁵, Shefali Sharma⁶ and Aman Sharma⁷, ¹Internal Medicine, Post Graduate Institute of Medical Education and Research (PGIMER), chandigarh, India, ²Internal medicine, Post graduate Institute of medical education and research, chandigarh, India, ³Internal Medicine ( Clinical Rheumatology), Post Graduate Institute of Medical Education and Research, chandigarh, India, ⁴Radio Diagnosis, Post Graduate Institute of Medical Education and Research, chandigarh, India, ⁵Department of Immunopathology,, PGIMER,, Chandigarh, India, ⁶Department of Medicine, All India Institute of Medical Sciences, New Delhi, New Delhi, India, ⁷Internal Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India
Background/Purpose: Mixed connective disease is a multi-system disorder with overlapping features of SLE, rheumatoid arthritis, scleroderma and polymyositis/dermatomyositis with high titres of U1 RNP. Arthritis…
Abstract Number: 948 • 2012 ACR/ARHP Annual Meeting
Antibody-Based Prediction Rules for Connective Tissue Disease: Analysis of 12,555 Patients with Antinuclear Antibody Testing
Ryo Rokutanda¹, Mitsumasa Kishimoto¹, Yasuharu Tokuda², Ken-ichi Yamaguchi¹, Hisanori Shimizu¹, Yasuhiro Suyama¹, Yuri Ohara¹, Yoichiro Haji¹, Chisun Min¹, Akira Takeda¹, Yukio Matsui³ and Masato Okada¹, ¹Division of Allergy and Rheumatology, St. Luke's International Hospital, Tokyo, Japan, ²Institute of Clinical Medicine, University of Tsukuba, Ibaraki, Japan, ³Immuno-Rheumatology Center, St. Luke's International Hospital, Tokyo, Japan
Background/Purpose: Antinuclear antibody (ANA) is widely used as a screening test for connective tissue diseases (CTDs). The sensitivity of this test is high in 3…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].